NVSTEnvista Holdings Corporation
Price
+9.8%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growing in the filings, the market undecided.
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Envista Holdings Corporation (NVST) reported revenue of $731M in Q2 2026 (quarter ended Jul 3, 2026), up 7.1% from the same quarter a year earlier. That came with a gross margin of 56% and net income of $54M (7.4% of revenue). For the full year FY2025, revenue was $2.72B (+8.3% year on year) and net income $47M. Its largest region in Q2 2026 was North America at $185M, 39% of the disclosed total, ahead of Western Europe at 28%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026Chief Executive Officer Compensation Changes Reference is made to the information contained in.Director or officer change · Form 8-K
- Aug 5, 2026Envista Reports Second Quarter 2026 Results.Earnings release · press release
- Jun 3, 2026On May 28, 2026, Faez Kaabi notified Envista Holdings Corporation (the “Company”) of his intention to resign as Chief Accounting Officer and principal accounting officer of the Company effective as of August 6, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $471.0MThe company’s own SEC segment disclosure.
- North America$184.7M39%
- Western Europe$133.2M28%
- High Growth Markets$128.7M27%
- Other Developed Markets$24.4M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #7 of 21 by RyuScore